Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV

JAMA

Volumn 308, Issue 4, 2012, Pages 370-378

  Limketkai, Berkeley N ^a   Mehta, Shruti H ^b   Sutcliffe, Catherine G ^b   Higgins, Yvonne M ^a   Torbenson, Michael S ^a   Brinkley, Sherilyn C ^a   Moore, Richard D ^a,b   Thomas, David L ^a,b   Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

EID: 84864129035     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.7844     Document Type: Article

References (35)

1. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288(2):199-206. (Pubitemid 34755280)
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831-837. (Pubitemid 34194855)
3. Kitahata MM, Gange SJ, Abraham AG, et al NAACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.
4. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virusco-infected adults. AIDS. 2007;21(16):2209-2216. (Pubitemid 350287219)
5. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: ameta-analysis. Clin Infect Dis. 2001;33(4):562-569. (Pubitemid 32709592)
6. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010;138(1):159-164.
7. Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing US multiple-cause-of-death data. Public Health Rep. 2010;125(3):414-422.
8. Chen TY, Ding EL, Seage Iii GR, Kim AY. Metaanalysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49(10):1605-1615.
9. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991.
10. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362(9397):1708-1713. (Pubitemid 37468321)
11. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
12. Rockstroh JK, Bhagani S, Benhamou Y, et al EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9(2):82-88. (Pubitemid 351228130)
13. Pineda JA, García-García JA, Aguilar-Guisado M, et al Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007;46(3):622-630. (Pubitemid 47436106)
14. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1 pt 1):15-20.
15. Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289-293. (Pubitemid 26260021)
16. Linas BP, Wang B, Smurzynski M, et al. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011;18(7):506-512.
17. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21(9):1073-1089. (Pubitemid 46763278)
18. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495-500. (Pubitemid 32164902)
19. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50(1):36-41.
20. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-2618.
21. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17(5):721-725. (Pubitemid 36521078)
22. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526. (Pubitemid 36919874)
23. Sterling RK, Lissen E, Clumeck N, et al APRI-COT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. (Pubitemid 43980111)
24. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009;48(7):963-972.
25. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41(2):175-179.
26. Morgan TR, Ghany MG, Kim HY, et al HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833-844.
27. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126-133.
28. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20(18):2361-2369. (Pubitemid 44789539)
29. Rodriguez-Torres M, Slim J, Bhatti L, et al Standard versus high dose ribavirin in combination with peginterferon alfa-2a in genotype 1 HCV patients coinfected with HIV: final results of the PARADIGM study. In: Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases. October 30-November 3, 2009; Boston, MA. Abstract 1561.
30. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
31. Jacobson IM, McHutchison JG, Dusheiko G, et al ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection.NEngl J Med. 2011;364(25):2405-2416.
32. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype1. N Engl J Med. 2012;366(3):216-224.
33. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 23, 2012.
34. Saunders JB, Aasland OG, Babor TF, de la Fuente JR,Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption - II. Addiction. 1993;88(6):791-804. (Pubitemid 23194530)
35. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology. 2005;41(1):123-131. (Pubitemid 40066390)